Viridian Therapeutics (NASDAQ:VRDN) Price Target Cut to $27.00 by Analysts at The Goldman Sachs Group
Viridian Therapeutics (NASDAQ:VRDN – Get Free Report) had its target price reduced by The Goldman Sachs Group from $31.00 to $27.00 in a note issued to investors on Wednesday,Benzinga reports. The firm presently has a “buy” rating on the stock. The Goldman Sachs Group’s price target would suggest a potential upside of 111.27% from the […]
Viridian Therapeutics (NASDAQ:VRDN – Get Free Report) had its target price reduced by The Goldman Sachs Group from $31.00 to $27.00 in a note issued to investors on Wednesday,Benzinga reports. The firm presently has a “buy” rating on the stock. The Goldman Sachs Group’s price target would suggest a potential upside of 111.27% from the […]
